Archives of General Internal Medicine

Reach Us +1 (202) 780-3397

Commentary - Archives of General Internal Medicine (2023) Volume 7, Issue 1

Advances in therapeutic drug monitoring and mycobacterial infections

Robert Woods*

Department of Pharmacy, Mayo Clinic, Rochester, United States

*Corresponding Author:
Robert Woods
Department of Pharmacy
Mayo Clinic, Rochester, United States

Received: 04-Jan-2023, Manuscript No. AAAGIM-23-89066; Editor assigned: 06-Jan-2023, PreQC No. AAAGIM-23-89066(PQ); Reviewed: 20-Jan-2023, QC No. AAAGIM-23-89066; Revised: 27-Jan-2023, Manuscript No. AAAGIM-23-89066(R); Published: 054-Feb-2023, DOI: 10.35841/aaagim-7.1.161

Citation: Woods R. Advances in therapeutic drug monitoring and mycobacterial infections. Arch Gen Intern Med 2023;7(1):161

Visit for more related articles at Archives of General Internal Medicine


Tuberculosis (TB) is a main source of irresistible passing. Nontuberculous mycobacteria (NTM) cause a wide assortment of challenging to-treat contaminations in different human hosts. Therapeutic drug monitoring (TDM) stays a standard clinical strategy that utilizes plasma drug focuses to decide portion. The motivation to do this is basic: drug openness (that is, the free medication region under the plasma focus time bend) comparative with the MIC and not the portion as such generally decides the result of the contaminations. TDM gives objective data that clinician can use to settle on informed dosing choices. The typical plasma fixation ranges give sensible direction to starting objective focuses. Clinicians then consolidate focus information with information about the patients, to choose how forceful to with portion.


Tuberculosis, Nontuberculous mycobacteria, Therapeutic drug monitoring.


Introduction Nontuberculous mycobacteria (NTM) are crafty microbes that can cause a great many sicknesses from insignificantly suggestive self-restricting contaminations to moderate and perilous illness of the respiratory framework, focal sensory system, lymph hubs, joints, skin, or the entire body (dispersed infection). The predominance of NTM is expanding in locales where revealing contamination is required or where reconnaissance studies have been performed with rates as high as 10 for each 100,000 populace in Australia and North America and 2 for every 100,000 in Europe. Patients with prior lung sicknesses including asthma, persistent obstructive pneumonic infection, cystic fibrosis, and bronchiectasis or with immunodeficiency’s (acquired or procured) are more powerless to NTM illness. Spread NTM illness generally appears in patients who are immunocompromised. Nontuberculous mycobacteria are more normal in individuals matured 50 years and more established. Furthermore, pneumonic NTM illness can happen in individuals with anatomic anomalies in the thoracic enclosure [1].

Microbiologically, NTM can be partitioned into slow-and fast developing species. Mycobacterium avium complex (Macintosh), M. intracellular, M. figment, M. kansasii, M. malmoense, and M. xenopi are the most often noticed sluggish developing species while the quick developing species incorporate M. abscessus perplexing and M. fortuitism complex. It is essential to recall that particular societies should be mentioned for the segregation of mycobacteria [2].

While settling on TDM-based choices, it is essential to incorporate the helplessness (least inhibitory fixation [MIC]) of the microorganism notwithstanding the medication openness as the MIC is remembered for all PK/PD boundaries (region under the focus time bend over MIC [AUC/MIC], most extreme focus over MIC [Cmax/MIC], and time above MIC [T>MIC]). Notwithstanding, exactness and measure variety should be represented while utilizing MICs revealed by clinical research centers [9]. Conversely, with M. tuberculosis, the connection between's way of life based drug-defenselessness test (DST) results for NTM and treatment results is profoundly factor contingent upon the NTM species and antimycobacterial specialist. The Clinical and Lab Guidelines Foundation (CLSI) suggests clarithromycin and amikacin weakness testing just for Macintosh, clarithromycin and rifampicin for M. kansasii, and clarithromycin [3].

Phenotypic weakness testing can be performed utilizing the stock microdilution strategy as indicated by CLSI suggestions or plate dissemination methods. Notwithstanding, the CLSI technique gives more strong breakpoints, normalization, and reproducibility. Arrangement between the two techniques is less solid for certain medications, for example, cefoxitin and amikacin and a portion of the breakpoint focuses for recognition of clinically important opposition in NTM stay questionable. The Macintosh breakpoints for amikacin have been as of late reexamined to incorporate separate qualities for intravenous and the more up to date liposomal definition of amikacin [4].

Sub-atomic instruments of inborn and obtained opposition against macrolides, aminoglycosides, linezolid, clofazimine, and bedaquiline have as of late been clarified. These advances empowered sub-atomic ways to deal with a DST. For instance, the NTM-DR pack (Hain Lifescience GmbH, Nehren, Germany) can distinguish natural and obtained opposition in NTM to macrolides and aminoglycosides by recognizing obstruction presenting changes in erm, rrl, and rrs qualities. Significantly, these sub-atomic methodologies can likewise recognize heteroresistance, i.e., the presence of safe subpopulation in any case phenotypically drug-powerless mycobacteria [5].


The treatment of NTM to a great extent has created in view of well-qualified assessment and extrapolation, utilizing accessible medications at the 'standard thing' dosages due to restricted information. Further clinical preliminaries including PK/PD examinations are earnestly required with an emphasis on more limited, better, and more okay treatment. Since numerous patients with aspiratory Macintosh and other NTM are more seasoned and slighter, drug narrow mindedness is normal. In any event, when confronted with estimated low plasma drug focuses, doctors frequently are hesitant to expand the portions on account of worries of unfavorable impacts.


  1. Cowman S, van Ingen J, Griffith DE, et al. Non-tuberculous mycobacterial pulmonary disease. Europ Respir J. 2019;54(1).
  2. Indexed at, Google Scholar, Cross Ref

  3. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin Chest Med. 2015;36(1):13-34.
  4. Indexed at, Google Scholar, Cross Ref 

  5. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res. 2017;4:e000242.
  6. Indexed at, Google Scholar, Cross Ref

  7. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.
  8. Indexed at, Google Scholar, Cross Ref

  9. Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med. 2015;36:1-11.
  10. Indexed at, Google Scholar, Cross Ref

Get the App